KRAS Mutations
The KRAS oncogene is frequently mutated in lung, colorectal and pancreatic cancers. At diagnosis, KRAS mutations are present, but patients will receive other treatments for their cancer.
Patient Journey
Lung Cancer
~30%
of lung carcinoma
patients have KRAS mutations
Colorectal Cancer
~40%
of colorectal cancer
patients have KRAS mutations
Pancreatic Cancer
~90%
of pancreatic cancer
patients have KRAS mutations
The Patient Journey
The KRAS oncogene is frequently mutated in lung, colorectal and pancreatic cancers. At diagnosis, KRAS mutations are present, but patients will receive other treatments for their cancer. Patient’s tumors are prone to molecular change over time and on treatment.
* KRASG12C drugs are approved for use in NSCLC [package insert for sotorasib, adagrasib]